The ninth annual event, taking place in Boston mid-November, will feature industry professionals addressing manufacturing practices, regulatory updates and market trends.
After receiving FDA approval, the pharmaceutical company has announced plans to launch a Phase I trial for an inhaled version of the COVID-19 treatment.
A leader with the industry association discusses the surging interest in harnessing artificial intelligence to advance various treatments and therapies.
The agency continues to offer advice related to drug development and clinical research during the pandemic, and take action against those falling out of line.
A representative of the research and development firm offers perspective on how the industry has shifted in recent years, thanks to a number of forces.
The pharmaceutical analysis firm is continuing its contract analytical laboratory services running, with changes designed to keep people and products safe.
With the acquisition of Weibel, SHL Medical looks to the development of novel drug delivery systems for self-administration, answering a need for improved patient-centricity in the sector.
Biohaven’s drug for acute treatment of migraine, manufactured using Catalent’s Zydis technology for orally disintegrating tablets, receives approval from the US FDA.
Abbott’s glucose sensing technology and a tubeless insulin delivery system developed by Insulet are set to create a personalized diabetes management solution.
Bioavailability of water insoluble compounds, such as CBD, enhanced up to 15 times with the technology of Solmic, leading to its acquisition by Betterlife.
Developers of generic drugs administered with topical drug delivery methods benefit from MedPharm’s in-vitro models to safely demonstrate bioequivalence.
Hikma taps Arestat, a formulation technology for protein- and peptide-based drugs, to develop an injectable medicine, ahead of filing for US FDA approval.
Representatives from companies providing recruitment services to the pharmaceutical industry discuss the challenges on ‘winning the talent war’ during Pharma Integrates.
Celltrion receives EMA marketing authorisation for Remsima SC, the first subcutaneously-administered option for delivery of infliximab, a treatment for rheumatoid arthritis.
Speaking at the FT Pharmaceutical & Biotechnology conference earlier this week, Ipsen’s CCO said that pharma manufacturers need to focus more on the ‘why’.
Sharp’s electronic label for drug packaging can be updated again and again, saving time and costs whilst also improving patient engagement during clinical trials.
While exhibiting its offering in self-administration devices at the CPhI Worldwide event in Frankfurt last week, West told us how patient convenience drives design and development.
Cycle looks to benefit from the advantages of Zydis oral disintegrating tablet technology, developed by Catalent, for four of its drug products treating rare diseases.
